Henry Ford Health

Henry Ford Health Scholarly Commons
Pharmacy Articles

Pharmacy

10-26-2022

Clinical Outcomes of Eravacycline in Patients Treated
Predominately for Carbapenem-Resistant Acinetobacter
baumannii
Sara Alosaimy
Taylor Morrisette
Abdalhamid M. Lagnf
Leonor M. Rojas
Madeline A. King

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/pharmacy_articles

Authors
Sara Alosaimy, Taylor Morrisette, Abdalhamid M. Lagnf, Leonor M. Rojas, Madeline A. King, Benjamin M.
Pullinger, Athena L. V Hobbs, Nicholson B. Perkins, Michael P. Veve, Jeannette Bouchard, Tristan Gore,
Bruce Jones, James Truong, Justin Andrade, Glen Huang, Reese Cosimi, S. Lena Kang-Birken, Kyle C.
Molina, Mark Biagi, Michael Pierce, Marco R. Scipione, Jing J. Zhao, Susan L. Davis, and Michael J. Rybak

RESEARCH ARTICLE

Clinical Outcomes of Eravacycline in Patients Treated
Predominately for Carbapenem-Resistant Acinetobacter
baumannii
Sara Alosaimy,a Taylor Morrisette,a* Abdalhamid M. Lagnf,a Leonor M. Rojas,b Madeline A. King,c,d Benjamin M. Pullinger,c,d
Athena L. V. Hobbs,e,f Nicholson B. Perkins III,g Michael P. Veve,a,h,i Jeannette Bouchard,j Tristan Gore,j Bruce Jones,k
James Truong,l Justin Andrade,l Glen Huang,m Reese Cosimi,n S. Lena Kang-Birken,o Kyle C. Molina,p Mark Biagi,q,r Michael Pierce,q
Marco R. Scipione,s Jing J. Zhao,t Susan L. Davis,a,i Michael J. Rybaka,s,u
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State
University, Detroit, Michigan, USA

a

Valley Hospital Medical Center, Las Vegas, Nevada, USA

b
c

Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, Pennsylvania, USA
Cooper University Hospital, Camden, New Jersey, USA

d

Methodist University Hospital, Memphis, Tennessee, USA

e

Cardinal Health, Memphis, Tennessee, USA

f

University of Tennessee Health Science Center College of Pharmacy, Memphis, Tennessee, USA

g
h
i

University of Tennessee Medical Center, Knoxville, Tennessee, USA

Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA
College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA

j

k
l

St. Joseph’s/Candler Health System, Savannah, Georgia, USA

The Brooklyn Hospital, Brooklyn, New York, USA
University of California Los Angeles, Los Angeles, California, USA

m
n

Ascension St. Vincent Hospital, Indianapolis, Indiana, USA

Santa Barbara Cottage Hospital, Santa Barbara, California, USA

o

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA

p

SwedishAmerican Hospital, Rockford, Illinois, USA

q

University of Illinois at Chicago, Rockford, Illinois, USA

r

Department of Pharmacy, Detroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan, USA

s

Department of Pharmacy, Harper University Hospital, Detroit Medical Center, Detroit, Michigan, USA

t

Department of Medicine, Division of Infectious Diseases, School of Medicine, Wayne State University,
Detroit, Michigan, USA

u

ABSTRACT

Forty-six patients were treated with eravacycline (ERV) for Acinetobacter
baumannii infections, where 69.5% of isolates were carbapenem resistant (CRAB). Infections
were primarily pulmonary (58.3%), and most patients received combination therapy (84.4%).
The median (IQR) ERV duration was 6.9 days (5.1 to 11.1). Thirty-day mortality was 23.9%
in the cohort and 21.9% in CRAB patients. One patient experienced an ERV-possible adverse
event.

IMPORTANCE Acinetobacter baumannii, particularly when carbapenem resistant (CRAB), is

one of the most challenging pathogens in the health care setting. This is complicated by
the fact that there is no consensus guideline regarding management of A. baumannii infections. However, the recent Infectious Diseases Society of America guidelines for treatment of
resistant Gram-negative infections provided expert recommendations for CRAB management.
The panel suggest using minocycline among tetracycline derivatives rather than eravacycline
(ERV) until sufﬁcient clinical data are available. Therefore, we present the largest multicenter
real-world cohort in patients treated with ERV for A. baumannii, where the majority of isolates were CRAB (69.5%). Our analysis demonstrate that patients treated with ERV-based
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regimens achieved a 30-day mortality of 23.9% and had a low incidence of ERV-possible
adverse events (2.1%). This study is important as it ﬁlls the gap in the literature regarding the use of a novel tetracycline (i.e., ERV) in the treatment of this challenging health
care infection.
KEYWORDS eravacycline, Acinetobacter baumannii, Acinetobacter, CRAB, Gramnegative bacteria, hospital infections, tetracyclines

A

cinetobacter baumannii is one of the most challenging pathogens in the health care
setting (1, 2). The attributable mortality in A. baumannii ventilator-associated pneumonia and bloodstream infections is as high as 54% in the intensive care unit. In fact, it is associated with the highest attributable costs compared to various resistant pathogens in both
community onset and hospital-onset invasive infections—up to $128,235 (3). Furthermore,
these isolates are often resistant to a wide number of antibiotic classes, such as ﬂuoroquinolones and polymyxins, and have the ability to rapidly acquire resistance to many agents,
such as carbapenem. Notably, carbapenem-resistant A. baumannii (CRAB) is considered to be
an urgent threat according to the most recent report from the Centers of Disease Control and
Prevention (CDC), due to a lack of available therapeutic options (4). There is no current consensus regarding a deﬁnition of treatment success for A. baumannii infections (5, 6). Regarding
CRAB management, however, the recent Infectious Diseases Society of America guidelines for
treatment of resistant Gram-negative infections provided expert recommendations (7). The
panel recommended treatment with a single agent, preferably ampicillin-sulbactam, for mild
CRAB infections. For moderate to severe CRAB, combination therapy with at least 2 agents,
preferably with in vitro activity, is suggested. Regarding the use of tetracycline (TET) derivatives
in CRAB, the panel suggest using minocycline or even high-dose tigecycline as alternative
rather than eravacycline (ERV) until more clinical data with ERV in CRAB become available.
ERV is a novel ﬂuorescein within the tetracycline (TET) class approved by the Food and
Drug Administration (FDA) for the treatment of complicated intra-abdominal infections (8).
Unlike real-world studies, clinical trials thus far have exclusively focused on the infection site
rather than the causative organism and are conducted under ideal conditions in patient
populations that are different from the daily clinical practice patient. In fact, although existing
clinical trials and/or real-world reports of ERV have been slowly emerging, only 15 patients
with A. baumannii were included (9–11). While these reports have described positive clinical
outcomes, the majority of these A. baumannii cases were not CRAB and/or their carbapenem
susceptibilities were not indicated. The objective of this study is to describe real-world experience with ERV for the treatment of A. baumannii, including CRAB, to evaluate its effectiveness
and adverse events.
RESULTS
Collectively, 46 patients who received ERV for A. baumannii were included (Table 1). The
median (interquartile range [IQR]) age was 62.5 years (52.5 to 76.0 years), and the majority of
patients were male (54.3%) and Caucasian (54.3%). The median (IQR) APACHE-II score was
15 (11 to 24), and many patients were in the intensive care unit at time of index culture
(41.3%). Medical comorbidities were common: primarily obesity (37.0%), diabetes (37.0%),
chronic pulmonary disease (30.4%), cerebrovascular disease (32.6%), and chronic kidney disease (23.9%). The majority of patients (91.3%) had at least one risk factor for multidrug-resistant infections: the most common was the use of antimicrobials for $24 h in the 90 days
before index culture (67.4%), followed by hospitalization for $48 h in the 90 days before
index culture 63.0%.
The majority of patients had an Infectious Diseases (ID) consultation (97.8%), and a
signiﬁcant proportion of patients were consulted for ID prior to the positive index culture
(37.2%). Among these consulted after positive culture (n = 27), the median (IQR) time to ID
consult was 37.6 h (1.5 to 80.6 h). Surgical interventions related to the infection source
were established in 37.0%. The sources of infection were variable, but pulmonary infection
(52.2%) was the most common, followed by skin/soft tissue (17.4%) and bone/joint (8.7%)
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TABLE 1 Patient demographics, clinical criteria and health outcomesa
Result forb:
Parameter
Age, yr, median (IQR)
Age of $65 yr, n (%)
Sex, male, n (%)

Population (n = 46)
62.5 (52.5–76)
20 (43.5)
25 (54.3)

CRAB (n = 32)
62.0 (53.0–77.0)
15 (46.9)
17 (53.1)

Race, n (%)
African-American
Caucasian
Other

13 (28.3)
25 (54.3)
8 (17.3)

7 (21.9)
20 (62.5)
5 (15.6)

wt, kg, median (IQR)
BMI, kg/m2, median (IQR)
BMI of $30

71.6 (60.2–91.2)
25.1 (22.0–33.5)
17 (37.0%)

79.3 (61.8–92.1)
25.7 (21.9–34.9)
13 (40.6%)

Baseline serum creatinine, mg/dL, median (IQR)
CLCR, mL/min, median (IQR)

0.80 (0.6–1.5)
18.6 (14.7–35.5)

0.85 (0.6–1.4)
19.0 (13.2–38.9)

Residence prior to admission, n (%)
Home
Transfer from outside hospital
Nursing home, skilled nursing facility, long term care facility
Otherc

19 (41.3)
5 (10.9)
18 (39.1)
4 (91.3)

11 (34.4)
5 (15.6)
16 (50.0)
0 (0)

Comorbid conditions
CCI, median (IQR)
CCI of $5, n (%)
Cerebrovascular disease, n (%)d
Chronic pulmonary disease, n (%)e
Moderate to severe kidney disease or on chronic dialysis, n (%)f
Connective tissue disease, n (%)g
Clostridiodes difﬁcile-associated diarrhea, n (%)
Dementia, n (%)
Diabetes, n (%)
Heart failure, n (%)
Hemiplegia, n (%)
Tumor without metastasis, n (%)
Tumor with metastasis, n (%)
Liver disease, n (%)
Myocardial infarction, n (%)
No other conditions, n (%)
Peptic ulcer disease, n (%)
Peripheral vascular disease, n (%)h
PWID, n (%)

4.0 (2.0–7.0)
21 (45.7)
15 (32.6)
14 (30.4)
11 (23.9)
3 (6.5)
3 (6.5)
8 (17.4)
17 (37.0)
11 (23.9)
6 (13.0)
3 (6.5)
4 (8.7)
1 (2.2)
2 (4.3)
6 (13.0)
4 (8.7)
3 (6.5)
3 6.5)

4.5 (2.0–6.8)
16 (50.0)
12 (37.5)
12 (37.5)
9 (28.1)
0 (0)
3 (9.4)
4 (12.5)
11 (34.4)
7 (21.9)
5 (15.6)
3 (9.4)
1 (3.1)
1 (3.1)
2 (6.3)
5 (15.6)
3 (9.4)
3 (9.4)
2 (6.3)

MDR risk factors, n (%)i
Admitted from nursing home or extended care facility
Chronic dialysis in 30 days before index culture
Colonization with resistant organisms
Home infusion therapy
Home wound care
Prior antimicrobials for .24 h in 90 days prior to index culture
Prior infection with resistant organisms at any time
Prior hospitalization for at least 48 h in 90 days prior to index culture
Prior surgery in 30 days preceding index culture

22 (47.8)
6 (13.0)
15 (32.6)
3 (6.5)
5 (10.9)
31 (67.4)
22 (47.8)
29 (63.0)
7 (15.2)

19 (59.4)
5 (15.6)
11 (34.4)
1 (3.1)
3 (9.4)
21 (65.6)
14 (43.8)
21 (65.6)
6 (18.8%)

Sources of infection, n (%)
Bone and joint
Intra-abdominal
Primary bacteremia
Pneumonia
Mechanically ventilated for 48 h prior to pneumoniaj
Skin and soft tissue

4 (8.7)
2 (4.3)
3 (6.5)
24 (52.2)
18 (75.0)
8 (17.4)

3, (9.4)
2, (6.3)
1, (3.1)
19, (59.4)
14, (73.7)
5 (15.6)
(Continued on next page)
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TABLE 1 (Continued)
Result forb:
Parameter
Urinary
Unknown
Otherk

Population (n = 46)
2 (4.3)
1 (2.2)
2 (4.3)

CRAB (n = 32)
0 (0)
0 (0)
2 (6.3)

Pathogens targeted beyond A. baumannii, n (%)
Enterobacter cloacae
Enterococcus faecalis
Enterococcus faecium
Escherichia coli
Klebsiella oxytoca
Klebsiella pneumoniae
Morganella morganii
Proteus mirabilis
Providencia stuartii
Staphylococcus aureus
Methicillin resistant
Stenotrophomonas maltophilia
Otherl

1 (2.2)
2 (4.3)
4 (8.7)
3 (6.5)
1 (2.2)
4 (8.7)
1 (2.2)
1 (2.2)
1 (2.2)
7 (15.2)
4 (8.7)
1 (2.2)
6 (13.0)

1 (3.1)
1 (3.1)
2 (6.3)
3 (9.4)
1 (3.1)
2 (6.3)
1 (3.1)
1 (3.1)
1 (3.1)
3 (9.4)
3 (9.4)
1 (3.1)
6 (18.8)

MIC
Ampicillin-sulbactam (n = 35), mg/L, median (range)
Susceptible, n (%)
Amikacin (n = 21), mg/L, median (range)
Susceptible, n (%)
Ceftazidime-avibactam (n = 1), mg/L
Colistin (n = 2), mg/L, median (range)
Intermediate, n (%)m
Eravacycline (n = 6), mg/L, median (range)n
Imipenem (n = 9), mg/L, median (range)
Susceptible, n (%)
Tigecycline (n = 17), mg/L, median (range)
Tobramycin (n = 38), mg/L, median (range)
Susceptible, n (%)
Meropenem (n = 37), mg/L, median (range)
Susceptible, n (%)
Meropenem-vaborbactam (n = 1), mg/L
Minocycline (n = 17), mg/L, median (range)
Susceptible

16.0 (2.0–32.0)
8/35 (22.9)
32.0 (4.0–256.0)
11/21 (52.4)
128
1.5 (1.0–2.0)
2/2 (100)
0.87 (0.125–1.50)
16.0 (0.25–16.0)
1/9 (11.11)
2.0 (0.5–4.0)
4.0 (1.0–16.0)
20/38 (52.6)
8.0 (0.25–16)
5/37 (13.5)
64.0
8.0 (1.0–32.0)
6/17 (35.3)

16.0 (4.0–32.0)
4/27 (14.8)
32.0 (10.0–32.0)
8/20 (40.0)
128
1.5 (1.0–2.0)
2/2 (100)
0.75 (0.5–1.0)
16.0 (8.0–16.0)
0/8 (0)
2.0 (1.0–4.0)
8.0 (1.0–16.0)
13/29 (44.8)
16.0 (8–16)
0/32 (0)
64.0
8.0 (2.0–32.0)
5/14 (35.7)

Markers of disease progression
APACHE II, median (IQR)
APACHE score of $15, n (%)
APACHE score of $30, n (%)

15.0 (11.0–24.0)
26 (56.5)
3 (9.4)

17.5 (10.3–24.8)
19 (59.4)
4 (8.7)

ERV
Duration, days, median (IQR)
Start from index culture, days, median (IQR)
Dosing, n (%)
1 mg/kg q12h
Othero

6.9 (5.1–11.1)
3.0 (2.0–5.7)

7.5 (5.4–11.9)
3.4 (2.3–5.5)

44 (95.7)
2 (4.3)

32 (100)
0 (0)

Treatment-related factors
Active antibiotics prior to ERV, n (%)p
Inhaled antibiotics, any, n (%)q
i.v. combination therapy for $48 h, n (%)
Amikacin
Ampicillin-sulbactam
Colistin
Meropenem
Polymyxin B
Otherr

16 (34.8)
12 (26.1)
39 (84.8)
4 (8.7)
6 (13.0)
4 (8.7)
8 (17.4)
4 (8.7)
13 (33.3)

11 (34.4)
10 (31.3)
24 (75.0)
3 (9.4)
6 (18.8)
4 (12.5)
0 (0)
4 (12.5)
7 (21.8)
(Continued on next page)
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TABLE 1 (Continued)
Result forb:
Parameter
Intensive care upon index culture, n (%)s
SOFA score, median (IQR)
Mechanical ventilation, n (%)
For $48 h
Surgery consult, n (%)
Source control, n (%)t
Infectious Diseases consult, n (%)
Within 48 hu

Population (n = 46)
19 (41.3)
4.0 (2.0–7.0)
18 (39.1)
18 (100)
17 (37.0)
20 (43.5)
45 (97.8)
34/45 (75.5)

CRAB (n = 32)
14 (43.8)
5.0 (2.3–7.0)
14 (43.8)
14 (100)
13 (40.6)
16 (50)
31 (96.9)
25/31 (80.6)

Switched to another agent, n (%)
Minocycline
Otherv

6 (13.0)
3 (6.5)
3 (6.5)

3 (9.4)
1 (3.1)
2 (6.2)

Clinical outcomes
30-day mortality, n (%)
90-day mortality, n (%)
30-day recurrence, n (%)
Excluding patients with 30-day mortality
30-day readmission, n (%)
Excluding patients with 30-day mortality
Symptoms of infection worsen or fail to resolve, n (%)
Excluding patients with 30-day mortality
LOS, median (IQR)
Total
Before index culture
ICU

11 (23.9)
14 (30.4)
10 (21.7)
7 (20.0)
7 (15.2)
6 (17.1)
13 (28.3)
7 (20.0)

7 (21.9)
10 (31.3)
8 (25.0)
6 (24.0)
5 (15.6)
4 (16.0)
9 (28.1)
4 (16.0)

21 (12.5–39.0)
13.6 (10.1–30.9)
23.0 (16.5–46.5)

22 (13.0–39.5)
14.3 (10.5–31.5)
23.5 (16.5–47.0)

ERV-possible adverse events, n (%)
Gastrointestinal

1 (2.2)

1 (3.1)

aAPACHE

II, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; CCI, Carlson comorbidity index; CLCR, creatinine clearance; CRAB, carbapenem-resistant
Acinetobacter baumannii; CD4, cluster of differentiation 4; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; HIV, human immunodeﬁciency
virus; LOS, length of stay; MDR, multidrug resistant; MEV, meropenem-vaborbactam; OA, osteoarthritis; PWID, person who injects drugs; q12h, every 12 h; SOFA, sequential
organ failure assessment; TIA, transient ischemic attack.
bData are presented as median (IQR) and/or n (percentage) as appropriate. MIC data are presented as median (range).
cLong-term acute care facility (n = 2) or unknown (n = 2).
dStroke or TIA.
eAsthma or COPD.
fHemodialysis or peritoneal dialysis.
gOsteoarthritis or rheumatic arthritis.
hDeep venous thrombosis, chronic venous disease.
iDeﬁned as nonsusceptible to $3 antimicrobial categories.
jSuggestive of ventilator-associated pneumonia.
kSacral wound (n = 1) and infected peritoneal dialysis site (n = 1).
lEnterobacter cloacae, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis, Providencia stuartii, Stenotrophomonas maltophilia (n = 1 each).
mThe CLSI has assigned only an intermediate or resistant interpretation for colistin activity: MICs of #2 mg/L and .2 mg/L for each designation, respectively.
nn = 6 used Etest for ERV MIC in three institutions. A fourth institution used the Kirby-Bauer disk diffusion susceptibility test (n = 2), where the zones of inhibition were
measured at 12 and 14 mm, respectively.
on = 1 received 0.78 mg per kg q12h (to round down to 100 mg), n = 1 received 4 doses of 1 mg/kg q12h and then 1.1 mg/kg (to round up to 75 mg).
pActive therapy before ERV was deﬁned as therapy deemed to have in vitro susceptibility for A. baumannii administered before ERV start date.
qColistin (n = 6), tobramycin (n = 4), and amikacin (n = 1).
rCefepime, ceﬁderocol, ceftriaxone, and tobramycin (n = 3 each) and ciproﬂoxacin (n = 1).
sSeventeen (89.5%) medical, 1 (5.3%) cardiac, and 1 (5.3%) surgical/trauma.
tDebridement (n = 7), incision and drainage (n = 3), intravenous catheter removal (n = 1), invasive device removal (n = 1), amputation (n = 1), other (n = 11).
uFrom index culture. If ID was consulted before, index culture time was considered to be within 0 h.
vAmpicillin-sulbactam (n = 2), meropenem (n = 1).

infections. A. baumannii was most commonly isolated from expectorated sputum (37.0%),
blood (17.4%), wound/tissue (17.4%), or bronchoalveolar lavage ﬂuid (6.5%). Among
patients with microbiological clearance (n = 10), the median (IQR) time to clear was 1.9
days (1.6 to 5.8 days). The sources of infection for patients who cleared were mostly respiratory tract (4/10), followed by skin, bone/joint, primary bacteremia, and intra-abdominal
(n = 1, each). Other pathogens were also isolated, mainly Staphylococcus aureus (15.2%),
followed by Enterococcus faecium and Klebsiella pneumoniae (8.7% each).
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The majority of patients received combination therapy (84.8%), with meropenem being
the most commonly used second agent (17.4%). When ERV was switched to another agent
(13.0%), minocycline was most frequently selected (6.5%).
Thirty-day mortality occurred in 23.9% of the entire cohort and 21.9% of patients with
CRAB. Thirty-day recurrence occurred in 21.7% and 25.0% of patients in the entire cohort
and CRAB cohort, respectively. Table 1 provides a detailed list of clinical criteria and outcomes
of patients for the entire cohort versus the CRAB cohort.
MIC values for ERV were tested using the Etest in six isolates from three institutions,
the median of which was 0.87 mg/L (range, 0.125 to 1.50 mg/L). In a fourth institution,
ERV susceptibility was evaluated using Kirby-Bauer disk diffusion for two isolates, of
which the median was 13.00 mm (range, 12 to 14 mm). On the other hand, MIC values
for other commonly utilized antimicrobials were available for all isolates, primarily for
meropenem (80.4%), ampicillin-sulbactam (76.0%), and amikacin (76.0%).
ERV was generally initiated early at a median (IQR) of 3.0 days (2.0 to 5.7 days) from the
index culture. All except two patients received the full recommended dose of ERV. The total
median duration of ERV was 6.9 days (5.1 to 11.1 days). Most patients received $2 combination intravenous (i.v.) antibiotics (84.8%), with the most common being meropenem (17.4%),
ampicillin-sulbactam (13.0%), and amikacin and colistin (8.7%, each).
Only one patient experienced an ERV-possible adverse event (gastrointestinal),
which was diarrhea grade I while on therapy, which occurred 10 days after initiation of
ERV. Nevertheless, this did not lead to drug discontinuation, and the patient did not
experience mortality, recurrence, readmission, or worsening of symptoms.
DISCUSSION
In this brief report, we present the largest real-world, observational analysis of treatment
outcomes for patients treated with ERV for an A. baumannii infection, which were predominantly carbapenem resistant. In vitro studies report ERV MIC90 ranges of 0.5 to 2 and 1 to 2
mg/L in A. baumannii and CRAB, respectively (8). The IGNITE1 trial (ClinicalTrials registration
no. NCT01844856). showed clinical cure with ERV in 8/8 A. baumannii patients, of which 2/2
were conﬁrmed carbapenemase producers (9). Similarly, the IGNITE4 trial (ClinicalTrials registration no. NCT01844856) demonstrated an ERV success rate (as prespeciﬁed by the FDA)
in 5/5 A. baumannii patients with complicated intra-abdominal infection (cIAI) (10).
Additionally, the IGNITE1 and IGNITE4 trials were limited to a speciﬁc infection site (i.e., cIAI)
rather than other sites with more common A. baumannii infections, such as pulmonary, blood,
and urine (12). We recently reported our early experience with ERV in the real-world setting
for various infection types, where 5/7 patients treated for A. baumannii experienced 30-day
survival (11). Collectively, the majority of patients described in the literature either were not
CRAB or carbapenem susceptibilities were not reported. It is challenging to extrapolate the
results of the few published postmarketing clinical experiences to A. baumannii patients seen
in the real-world clinical setting.
In this cohort, we reviewed outcomes of patients with A. baumannii treated with ERV for
various infections, including cIAI, and with nearly 70% of isolates being CRAB. Compared to
other historical treatment options for CRAB, such as colistin and the newer cephalosporin
agents, such as ceﬁderocol, ERV 30-day survival was promising at nearly 75% (12, 13). When
ERV was switched to another agent, minocycline was the most common agent selected,
probably due to oral availability.
Nearly 85% of patients in our cohort received combination antibiotics with ERV as
observed in most A. baumannii reports, particularly when patients present with CRAB. That
was not surprising because combination approaches that include a carbapenem, polymyxin
B, and/or ampicillin-sulbactam are often advocated for vulnerable and critically ill patients
infected with CRAB (14). Albeit evidence is not optimum, the use of combination therapy is
hypothesized to increase the likelihood of adequate empirical antibiotic coverage before
drug susceptibility testing results are available, overcome multiple mechanisms of resistance,
decrease risk of emergent resistance, and improve clinical outcomes (5, 6, 14). However,
because it does not allow for any reductions in the dosing of a single agent, combination
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therapy introduces undeniable concerns about toxicities. The incidence of kidney injury with
meropenem and polymyxin combination-based therapies can be up to 50% and gastrointestinal side effects up to 27% (12). Therefore, the need for novel effective agents that are
also safe is of utmost importance. The incidence of ERV adverse events in our entire cohort
was minimal: only one patient experienced a possible adverse event. Nevertheless, this did
not lead to drug discontinuation or therapy changes and the patient achieved positive clinical
outcomes. Interestingly this incidence is far less than what was reported in the clinical trials
and real-world analyses, although larger studies are needed to evaluate this impact (8–11).
Our study is not without limitations. First, our inclusion criteria were conditioned on
ERV utility for 72 h regardless of culture date and time. While there might be a concern
for potential survival bias, it would not be appropriate to assume clinical outcomes for
ERV-treated patients if the treatment period was too brief. The median duration of ERV
in our cohort was ;1 week, and the median time to ERV start was timely at a median of
72 h from culture. It is well recognized that time to start effective therapy is an integral factor
in clinical success, particularly in Gram-negative infections. Additionally, duration of therapy
for A. baumannii regardless of infection type is typically no less than 7 days. Notably, none
of the patients included in our analyses were solid organ or bone marrow transplant recipients (15). It remains unclear if this high-risk population would achieve similar clinical beneﬁts
to the population in our cohort. Furthermore, it remains a challenge to draw conclusions
about toxicity and adverse events, particularly if the duration of ERV therapy was brief.
Finally, MICs for ERV were reported for a few but not the majority of isolates. It is challenging
to guarantee that all collaborating sites would perform ERV MIC testing, particularly at an
early stage of ERV adaptation. By MIC comparison, ERV MICs are at least 2-fold lower than
tigecycline MICs in A. baumannii (7). In our cohort, tigecycline testing (n = 17) was almost
three times more common than ERV testing (n = 6). While this may suggest that clinicians
are utilizing tigecycline susceptibility to guide ERV selection, the ability to correlate tigecycline MICs to ERV susceptibility and to clinical success remains unknown. Due to the above
considerations, further studies are needed to guide ERV selection in A. baumannii, particularly when tigecycline MICs are deemed susceptible.
Given the limited therapeutic options against A. baumannii, clinicians should be encouraged to report their experience with ERV given the potential it has for this challenging pathogen. Larger, prospective studies are necessary to assess the impact of ERV in combination with
other antibiotics, particularly in patients with CRAB. Finally, studies evaluating ERV versus tigecycline or other comparator agents, particularly in pneumonic and septic patients, are highly
warranted.
MATERIALS AND METHODS
Our study was a real-world, multicenter, retrospective observational evaluation at 14 geographically distinct
medical centers in the United States between September 2018 and March 2021. We included patients who were
(i) $18 years of age, (ii) had A. baumannii-positive cultures, and (iii) had been treated with ERV for $72 h.
Common clinical comorbidities and markers of disease progression were collected. The primary outcome was 30day mortality. Secondary outcomes included 30-day recurrence, resolution of signs and symptoms of infections,
30-day readmission, 90-day readmission, and occurrence of ERV-possible adverse effects (AE) using the common
terminology criteria for adverse events (CTCAE). Resolution of signs and symptoms was deﬁned as resolution or
improvement of infection-related abnormal white blood cells/temperature or as documented by the physician in
clinical notes. Thirty-day recurrence was deﬁned as culture positive for the same organism isolated from the index
culture counted 30 days from the end of ERV treatment. Combination therapy was deﬁned as any therapy used
in tandem with ERV for $48 h targeted for A. baumannii. Active therapy before ERV was deﬁned as therapy
deemed to have in vitro susceptibility for A. baumannii administered before the ERV start date. For A. baumannii,
susceptibility was interpreted using the Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints when applicable to drugs such as minocycline and tetracycline. When CLSI information was not available,
the FDA antibacterial susceptibility interpretive criteria were used if available (16). Descriptive statistics were utilized for data analysis using IBM SPSS software version 27.0 (SPSS, Inc., Chicago, IL, USA).
Ethical review. This study design and work had been reviewed and approved by the Wayne State
University Human Investigational Review Board and the DMC Research Review Committee prior to initiation. A patient consent statement was not required for this retrospective analysis.
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